ST
Therapeutic Areas
Ionis Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TRYNGOLZA (olezarsen) | Familial Chylomicronemia Syndrome (FCS) | Approved |
| Olezarsen sNDA | Severe Hypertriglyceridemia | NDA Review |
| DAWNZERA (donidalorsen) | Hereditary Angioedema | Phase 3 |
| Vitravene (fomivirsen) | CMV-induced retinitis | Approved |
| SPINRAZA (nusinersen) | Spinal Muscular Atrophy | Approved |
Leadership Team at Ionis Pharmaceuticals
BP
Brett P. Monia
Chief Executive Officer
BB
Brian Birchler
Executive Vice President, Corporate and Development Operations
CF
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
LP
Lynne Parshall
Board of Directors (retiring June 2026)
JW
Joseph Wender
Board of Directors (retiring June 2026)
PR
Peter Reikes
Incoming Board Member